Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Neurofibroma

• Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
• Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
• Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
• Dosing and Tolerability of Deoxycholic Acid Versus Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
• A Study of Avutometinib for People With Solid Tumor Cancers
• Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study
• Doxycycline in Cutaneous Schwannoma (NF2)
• DPCP to Treat Cutaneous Neurofibromas Associated With NF1
• HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
• Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
• Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
• A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis
• Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Toxicity of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
• A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
• NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
• Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
• Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
• Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
• Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
• A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
• A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
• Selumetinib Paediatric NF1 Japan Study
• Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
• Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1
• A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
• NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
• Innovative Trial for Understanding the Impact of Targeted Therapies in NF2
• Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
• A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
• Pediatric Long-Term Follow-up and Rollover Study
• MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
• A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
• From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1
• Treatment of NF1-related Plexiform Neurofibroma With Trametinib
• Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
• A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants
• Dexmedetomidine and Propofol for Pediatric MRI Sedation
• SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
• Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
• Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
• Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
• A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
• Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
• Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
• Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
• Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1
• Study of Aspirin in Patients With Vestibular Schwannoma
• Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma
• Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors
• Interventions for Reading Disabilities in NF1
• Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
• Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
• AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
• Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
• A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
• Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
• PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
• Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma
• Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
• MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
• PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
• Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
• Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
• Effect of Lamotrigine on Cognition in NF1
• Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
• Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
• Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
• Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Muta
• Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
• Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
• MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
• SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
• Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)
• Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
• Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
• Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
• Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
• SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
• Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
• Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
• Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
• Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
• Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
• Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
• Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas
• Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
• Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
• AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
• Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
• Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
• Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
• Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
• Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
• Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
• Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
• PTC299 for Treatment of Neurofibromatosis Type 2
• Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)
• Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
• Concentration and Activity of Lapatinib in Vestibular Schwannomas
• A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
• Medical Treatment of "High-Risk" Neurofibromas
• Sorafenib and Dacarbazine in Soft Tissue Sarcoma
• Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
• Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
• Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
• Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas
• Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
• A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
• Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
• Trial of Dasatinib in Advanced Sarcomas
• Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
• Study of PEG-Intron for Plexiform Neurofibromas
• Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
• Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
• AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
• Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
• NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate
• Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
• S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
• Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
• Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
• R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas